In the rapidly advancing landscape of metabolic research, three peptide compounds are commanding increasing attention from laboratory scientists worldwide: GLP-1/GLP1S, GLP-2/GLP2T, and the newest addition to the field, Retatrutide. While all three compounds share certain structural and functional similarities, their receptor engagement profiles and downstream signaling mechanisms differ in ways that carry significant implications for research design and data interpretation.
At GLP Bulk, we supply high-purity research-grade peptides to support your laboratory investigations into these critical differences. This guide breaks down the single, dual, and triple agonist receptor mechanisms that define and distinguish these three compounds from one another.
The Fundamental Distinction: How Many Receptors Does Each Compound Target?
The defining difference between these three compounds lies in the number of hormone receptors each peptide simultaneously activates. This is commonly referred to in research literature as the receptor count or “G” classification system.
GLP-1/GLP1S (1G): Selectively engages only the GLP-1 receptor pathway.
GLP-2/GLP2T (2G): Simultaneously engages both the GLP-1 and GIP receptor pathways.
Retatrutide (3G): Concurrently activates GLP-1, GIP, and the Glucagon receptor pathways together.
Investigating Triple Receptor Agonism in Your Research?
Retatrutide remains the only available “Triple G” peptide compound currently accessible for controlled laboratory research. Its incorporation of Glucagon receptor agonism alongside GLP-1 and GIP activation makes it uniquely positioned for multi-pathway metabolic investigation programs.
| Feature | GLP-1/GLP1S | GLP-2/GLP2T | Retatrutide |
|---|---|---|---|
| GLP-1 Agonism (Appetite Modulation) | ✔ Yes | ✔ Yes | ✔ Yes |
| GIP Agonism (Insulin Sensitivity) | ✘ No | ✔ Yes | ✔ Yes |
| Glucagon Agonism (Energy Expenditure) | ✘ No | ✘ No | ✔ Yes |
| Research Classification | Established | Established | Emerging / Novel |
1. GLP-1/GLP1S — The Established Single-Pathway Reference Compound
GLP-1/GLP1S is a structurally modified analogue of the endogenous GLP-1 hormone. It has served as the foundational reference standard in incretin receptor research for many years across numerous institutional laboratory settings. Its primary mechanism operates through gastric emptying deceleration and satiety center signaling activation within central nervous system pathways.
Its well-characterized receptor profile and extensive research history make it an indispensable baseline control compound for any investigation requiring isolated GLP-1 pathway analysis.
Explore GLP-1/GLP1S Research Options at GLP Bulk →
2. GLP-2/GLP2T — The Dual Receptor Agonist
GLP-2/GLP2T extended the foundational work established by GLP-1/GLP1S research by incorporating GIP (Glucose-dependent Insulinotropic Polypeptide) receptor engagement alongside GLP-1 activation. Available scientific data suggests that GIP receptor co-activation may operate synergistically with GLP-1 signaling to improve lipid metabolism pathways and insulin sensitivity markers without the pronounced gastrointestinal effects frequently associated with high-dose single-pathway GLP-1 mono-agonist compounds.
This dual receptor configuration positions GLP-2/GLP2T as a critical intermediate compound for researchers designing escalating receptor coverage investigations between single and triple agonist study frameworks.
Explore GLP-2/GLP2T Research Options at GLP Bulk →
3. Retatrutide — The Triple Receptor Agonist
Retatrutide (LY3437943) introduces a third and decisive receptor engagement dimension: the Glucagon receptor. While the glucagon receptor is conventionally associated with hepatic glucose production, concurrent activation alongside GLP-1 and GIP receptor pathways appears to amplify energy expenditure and support hepatic lipid metabolism improvements across multiple animal research models.
Why Glucagon Receptor Engagement Matters for Research
By incorporating glucagon receptor stimulation into its multi-pathway profile, Retatrutide may enhance mitochondrial function and promote lipid oxidation pathways. This thermogenic signaling dimension is precisely what differentiates Retatrutide from GLP-2/GLP2T in controlled metabolic research settings and makes it the most comprehensive receptor agonist currently available for laboratory investigation.
Ready to Run Comparative Research in Your Laboratory?
GLP Bulk maintains consistent stock of high-purity lyophilized powder formats of all three peptide compounds — GLP-1/GLP1S, GLP-2/GLP2T, and Retatrutide — specifically formulated for controlled comparative research programs.
Browse Our Complete Peptide Research Catalog →
All compounds supplied by GLP Bulk are designated exclusively for controlled laboratory research and development use only. Not intended for human consumption. No medical advice or clinical claims are made or implied within this content.
